Furthermore, with the use of small molecular inhibitors in CSCs and tumours to enhance the sensitivity of these cells to TRAIL or MSC-TRAIL mediated inhibition, better treatment efficacy can be achieved. The gene discussed is TNFSF10; the disease is neoplasm.